BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 35528782)

  • 1. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Pones M; D'Andrea D; Mori K; Abufraj M; Moschini M; Comperat E; Shariat SF
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
    Tan WS; Grajales V; Contieri R; Hensley P; Bree K; Msaouel P; Guo CC; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
    Eur Urol Open Sci; 2023 Jul; 53():16-22. PubMed ID: 37441349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
    Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
    Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
    Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
    Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
    Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
    BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E; Kikuchi E; Fukumoto K; Shirotake S; Miyazaki Y; Hakozaki K; Kaneko G; Yoshimine S; Tanaka N; Takahiro M; Kanai K; Oyama M; Nakajima Y; Hara S; Monma T; Oya M
    Clin Genitourin Cancer; 2018 Oct; 16(5):e969-e976. PubMed ID: 29778322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
    Hinsenveld FJ; Boormans JL; van der Poel HG; van der Schoot DKE; Vis AN; Aben KKH; Arends TJ; Ausems PJ; Baselmans D; Berger C; Berrens A; Bickerstaffe H; Bos SD; Braam M; Buddingh KT; Claus S; Dekker K; van Doeveren T; Einerhand S; Fossion L; van Gennep EJ; van Ginkel N; Palacios G; Hermans T; Hobijn MM; van Huystee SH; Jaspers-Valentijn M; Klaver OS; Koldewijn EL; Korsten L; Lenting A; Lentjes KJ; Luiting HB; van der Meer S; Nieuwenhuijzen JA; Noordzij MA; Nooter RI; Notenboom C; Oomen R; van Roermund J; de Rooij J; Roshani H; Schrier BP; van der Slot MA; Somford DM; Stelwagen PJ; Stroux A; van der West A; Wijsman BP; Windt W; van Zanten P; van Beek SC;
    Urol Oncol; 2022 Feb; 40(2):60.e1-60.e9. PubMed ID: 34303597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
    McFadden J; Tachibana I; Adra N; Collins K; Cary C; Koch M; Kaimakliotis H; Masterson TA; Rice KR
    Urol Oncol; 2024 Mar; 42(3):69.e11-69.e16. PubMed ID: 38267301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.
    Nouhaud FX; Chakroun M; Lenormand C; Ouzaid I; Peyronnet B; Gryn A; Prudhomme T; Grafeille V; Soulié M; Roumiguié M; Verhoest G; Xylinas E; Bouzouita A; Chebil M; Pfister C
    Urol Oncol; 2021 Mar; 39(3):195.e1-195.e6. PubMed ID: 33214030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
    Kool R; Marcq G; Breau RH; Black PC; Shayegan B; Kim M; Busca I; Abdi H; Dawidek MT; Uy M; Fervaha G; Cury FL; Alimohamed NS; Izawa JI; Jeldres C; Rendon R; Siemens DR; Kulkarni GS; Kassouf W
    Eur Urol Oncol; 2023 Dec; 6(6):597-603. PubMed ID: 37005214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications.
    Haas M; Knobloch C; Mayr R; Gierth M; Pickl C; Engelmann S; Denzinger S; Burger M; Breyer J; Holbach S
    Urol Int; 2023; 107(3):246-256. PubMed ID: 36693329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre.
    Pang KH; Thomas F; Novara G; Din OS; Morgan SL; Hussain SA; Jubber I; Noon AP; Catto JWF; Rosario DJ
    Eur Urol Focus; 2021 May; 7(3):554-565. PubMed ID: 32576531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
    Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
    Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
    Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience.
    Khanna A; Miest T; Sharma V; Campbell R; Hensley P; Thapa P; Zganjar A; Tollefson MK; Thompson RH; Frank I; Karnes RJ; Murthy PB; Haber GP; Navai N; Kamat AM; Dinney C; Lee B; Boorjian SA
    J Urol; 2022 Mar; 207(3):551-558. PubMed ID: 34694143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion: a propensity score-matched case control study.
    Yao Z; Jiang Y; Zhu X; Wu B; Bai S
    Int J Clin Oncol; 2020 Jul; 25(7):1377-1384. PubMed ID: 32318904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.